Related Experiment Video
Updated: Feb 10, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
A Convergence-Based Framework for Cancer Drug Resistance
David J Konieczkowski1, Cory M Johannessen2, Levi A Garraway3
1Harvard Radiation Oncology Program, Boston, MA 02114, USA.
Abstract:
Despite advances in cancer biology and therapeutics, drug resistance remains problematic. Resistance is often multifactorial, heterogeneous, and prone to undersampling. Nonetheless, many individual mechanisms of targeted therapy resistance may coalesce into a smaller number of convergences, including pathway reactivation (downstream re-engagement of original effectors), pathway bypass (recruitment of a parallel pathway converging on the same downstream output), and pathway indifference (development of a cellular state independent of the initial therapeutic target). Similar convergences may also underpin immunotherapy resistance. Such parsimonious, convergence-based frameworks may help explain resistance across tumor types and therapeutic categories and may also suggest strategies to overcome it.
Insights
Drug resistance in cancer is complex but may stem from a few key convergence mechanisms. Understanding these pathways, like reactivation or bypass, can help develop new cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Drug resistance is a major challenge in cancer treatment, despite advances in targeted therapies and immunotherapy.
- Mechanisms of resistance are often multifactorial and complex, making them difficult to fully understand and address.
Purpose of the Study:
- To propose a parsimonious framework for understanding drug resistance in cancer.
- To identify common convergence mechanisms underlying targeted therapy and immunotherapy resistance.
Main Methods:
- Conceptual analysis of existing data on cancer drug resistance mechanisms.
- Identification of recurring patterns in how resistance develops across different cancer types and treatments.
Main Results:
- Identified three primary convergence mechanisms: pathway reactivation, pathway bypass, and pathway indifference.
- These convergences may explain resistance to both targeted therapies and immunotherapies.
- The framework suggests potential common strategies to overcome resistance.
Conclusions:
- A convergence-based framework simplifies the understanding of complex drug resistance.
- This model provides insights into resistance across diverse cancer types and therapeutic modalities.
- The identified convergences offer potential targets for novel therapeutic strategies to overcome resistance.
Related Concept Videos
Convergent Evolution
Treatment Resistant Cancers
Region of Convergence
Convergence of Fourier Series
The Gibbs phenomenon refers to the persistent oscillations and overshoots that occur near discontinuities...
Region of Convergence of Laplace Tarnsform
Consider a decaying exponential signal that begins at a specific time. When deriving its Laplace transform, the time-domain variable is replaced with a complex variable. This...
Resistivity

